Abstract
Smad7 is an inhibitory Smad protein that blocks Transforming Growth Factor-beta (TGF-β) signaling through a negative feedback loop, also capable of mediating the crosstalk between TGF-β and other signaling pathways. Smad7 mRNA and protein levels are upregulated after TGF-β signaling; subsequently, Smad7 protein binds TGF-β type I receptor blocking R-Smad phosphorylation and eventually TGF-β signaling. Because of this inhibitory function, Smad7 can antagonize diverse cellular processes regulated by TGF-β such as cell proliferation, differentiation, apoptosis, adhesion and migration. Smad7 induction by different cytokines, besides TGF-β, is also critical for crosstalk/integration of a variety of signaling pathways, and relevant in the pathology of some diseases. Thus, Smad7 plays a key role in the control of various physiological events, and even in some pathological processes including fibrosis and cancer. This review highlights the main known functions of Smad7 with a particular focus on the relevance that alterations of Smad7 function may have in homeostasis, also describing some Smad7 emerging roles in the development of several human diseases that identify this protein as a potential therapeutic target.
Keywords: ALK5, cancer, fibrosis, Smad, Smad7, TGF, POSTTRANSLATIONAL MODIFICATIONS, SIGNALING PATHWAYS, cell proliferation, apoptosis
Current Molecular Pharmacology
Title: Inhibitory Smad7: Emerging Roles in Health and Disease
Volume: 4
Author(s): Marco A. Briones-Orta, Angeles C. Tecalco-Cruz, Marcela Sosa-Garrocho, Cassandre Caligaris and Marina Macias-Silva
Affiliation:
Keywords: ALK5, cancer, fibrosis, Smad, Smad7, TGF, POSTTRANSLATIONAL MODIFICATIONS, SIGNALING PATHWAYS, cell proliferation, apoptosis
Abstract: Smad7 is an inhibitory Smad protein that blocks Transforming Growth Factor-beta (TGF-β) signaling through a negative feedback loop, also capable of mediating the crosstalk between TGF-β and other signaling pathways. Smad7 mRNA and protein levels are upregulated after TGF-β signaling; subsequently, Smad7 protein binds TGF-β type I receptor blocking R-Smad phosphorylation and eventually TGF-β signaling. Because of this inhibitory function, Smad7 can antagonize diverse cellular processes regulated by TGF-β such as cell proliferation, differentiation, apoptosis, adhesion and migration. Smad7 induction by different cytokines, besides TGF-β, is also critical for crosstalk/integration of a variety of signaling pathways, and relevant in the pathology of some diseases. Thus, Smad7 plays a key role in the control of various physiological events, and even in some pathological processes including fibrosis and cancer. This review highlights the main known functions of Smad7 with a particular focus on the relevance that alterations of Smad7 function may have in homeostasis, also describing some Smad7 emerging roles in the development of several human diseases that identify this protein as a potential therapeutic target.
Export Options
About this article
Cite this article as:
A. Briones-Orta Marco, C. Tecalco-Cruz Angeles, Sosa-Garrocho Marcela, Caligaris Cassandre and Macias-Silva Marina, Inhibitory Smad7: Emerging Roles in Health and Disease, Current Molecular Pharmacology 2011; 4 (2) . https://dx.doi.org/10.2174/1874467211104020141
DOI https://dx.doi.org/10.2174/1874467211104020141 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Genistein Aglycone: A Dual Mode of Action Anti-Osteoporotic Soy Isoflavone Rebalancing Bone Turnover Towards Bone Formation
Current Medicinal Chemistry Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Apicidin Inhibited Proliferation and Invasion and Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 Cells
Anti-Cancer Agents in Medicinal Chemistry SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Biotransformations of Prenylated Hop Flavonoids for Drug Discovery and Production
Current Drug Metabolism Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets